Literature DB >> 2127586

Hepatitis C virus infection in individuals with or without human immunodeficiency virus type 1 infection.

A Sönnerborg1, A Abebe, O Strannegård.   

Abstract

Serum specimens from 111 human immunodeficiency virus type 1 (HIV-1) infected and 183 HIV-1 seronegative patients were analysed for antibodies to hepatitis C virus (HCV), hepatitis B virus (HBV) and hepatitis A virus (HAV) by enzyme linked immunoassay (ELISA) and radioimmunoassay. Anti-HCV and anti-HBV antibodies were found in the vast majority (89 and 83%, respectively) of intravenous drug addicts (IVDA), independent of the type of drug abuse or whether the patients were HIV-1 infected or not. Anti-HAV antibodies were found in 60% of the IVDA. Anti-HCV antibodies were found in anti-HIV-1 positive homosexual men (14%) and anti-HIV-1 negative heterosexual persons (8%), but not in HIV-1 seronegative homosexual men. Also anti-HAV antibodies were found to a small extent in these groups. In contrast, anti-HBV antibodies were common in the homosexual men. The absorbance values of the positive reactions in the anti-HCV ELISA were lower for HIV-1 seropositive patients than those for HIV-1 seronegative subjects, particularly in the late stages of HIV-1 infection. These data suggest that HCV infection is transmitted as readily as HBV infection by intravenous drug abuse and that all three types of hepatitis virus infection are common in IVDA. Although transmission of HCV is primarily mediated by blood, sexual transmission may also occur. HIV-1 infection seems to be associated with unusually low levels of anti-HCV antibodies, especially in the late stages of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2127586     DOI: 10.1007/bf01646402

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  14 in total

1.  Correlation of hepatitis C virus antibodies with HIV-1 seropositivity in intravenous drug addicts.

Authors:  H P Huemer; W M Prodinger; C Larcher; L Möst; M P Dierich
Journal:  Infection       Date:  1990 Mar-Apr       Impact factor: 3.553

2.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

3.  Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.

Authors:  J M Lange; D A Paul; H G Huisman; F de Wolf; H van den Berg; R A Coutinho; S A Danner; J van der Noordaa; J Goudsmit
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-06

4.  Hepatitis C virus antibody.

Authors:  P P Mortimer; B J Cohen; P A Litton; E M Vandervelde; M F Bassendine; A M Brind; M H Hambling
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

5.  The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men.

Authors:  N Bodsworth; B Donovan; B N Nightingale
Journal:  J Infect Dis       Date:  1989-10       Impact factor: 5.226

6.  Increased occurrence of hepatitis A with cyclic outbreaks among drug addicts in a Swedish community.

Authors:  A Widell; B G Hansson; T Moestrup; E Nordenfelt
Journal:  Infection       Date:  1983 Jul-Aug       Impact factor: 3.553

7.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

8.  Immune responses to fractionated cytomegalovirus (CMV) antigens after HIV infection. Loss of cellular and humoral reactivity to antigens recognized by HIV-, CMV+ individuals.

Authors:  P J Converse; T E Fehniger; A Ehrnst; O Strannegård; S Britton
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

9.  Chronic non-A, non-B hepatitis developed after transfusions, illicit self-injections or sporadically. Outcome during long-term follow-up--a comparison.

Authors:  L Mattsson; O Weiland; H Glaumann
Journal:  Liver       Date:  1989-04

10.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

View more
  5 in total

1.  HCV status knowledge and risk behaviours amongst intravenous drug users.

Authors:  G Vidal-Trécan; J Coste; I Varescon-Pousson; B Christoforov; A Boissonnas
Journal:  Eur J Epidemiol       Date:  2000-05       Impact factor: 8.082

Review 2.  Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.

Authors:  M Barry; S Gibbons; D Back; F Mulcahy
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

3.  Hepatitis C virus antibodies in homosexual men and intravenous drug users in Denmark.

Authors:  H Westh; A M Worm; B L Jensen; S Kroon; B Kvinesdal; C M Nielsen; P Wantzin
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

4.  Longitudinal study of cytomegalovirus antibodies in individuals infected with the human immunodeficiency virus.

Authors:  R W Flø; G Haukenes; A Nilsen; R Skjaerven; M Forsgren; T E Fehniger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

5.  Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia.

Authors:  Wei Zhang; Michael A Nardi; William Borkowsky; Zongdong Li; Simon Karpatkin
Journal:  Blood       Date:  2008-11-20       Impact factor: 22.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.